As PAX3 is predominantly expressed during embryogenesis and in malignant cells, and is absent in differentiated tissues, anti-PAX3 therapies might selectively target cancer cells, thus avoiding toxicity to normal cells. This evidence concerns the gene PAX3 and cancer.